Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2019-12

AUTHORS

E. V. McCloskey, L. A. Fitzpatrick, M.-Y. Hu, G. Williams, J. A. Kanis

ABSTRACT

We evaluated the efficacy of abaloparatide in women who were at increased risk for fracture, based on CHMP recommended risk thresholds, at the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) study baseline. Among patients at high risk based on FRAX probabilities, 18 months of abaloparatide significantly decreased risk for all fracture endpoints compared with placebo. PURPOSE: Abaloparatide, a novel anabolic agent for the treatment of postmenopausal osteoporosis, significantly reduced the risk of vertebral and nonvertebral fractures in the ACTIVE study compared with placebo. In this post hoc analysis, we evaluated abaloparatide's efficacy in a subset of women in the study at an increased risk of fracture at baseline, based on the Committee for Medicinal Products for Human Use (CHMP) recommended risk thresholds for inclusion in clinical trials. METHODS: Women with a baseline 10-year risk of major osteoporotic fracture ≥ 10% or hip fracture ≥ 5%, assessed using the FRAX® tool (including femoral neck bone mineral density), were included in the analysis. The proportion with one or more events of new morphometric vertebral fractures was calculated. Event rates for nonvertebral, major osteoporotic, and all clinical fractures were estimated using Kaplan-Meier analysis. RESULTS: Following 18 months of treatment, abaloparatide significantly reduced incident vertebral fractures compared with placebo (relative risk reduction = 91%; 0.5% versus 5.6%; p < 0.001). Abaloparatide treatment was also associated with significantly fewer nonvertebral, major osteoporotic, and clinical fractures compared with placebo: 2.7% versus 5.8%, p = 0.036; 1.3% versus 6.0%, p < 0.001; and 3.5% versus 8.2%, p = 0.006, respectively. The effect of abaloparatide on major osteoporotic fractures (78% reduction) was significantly greater than that seen with teriparatide (23% reduction, p = 0.007). CONCLUSION: In a subset of postmenopausal women at increased risk of fracture as judged by CHMP guidance, abaloparatide significantly decreased the risk of all fracture endpoints compared with placebo. More... »

PAGES

15

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11657-019-0564-7

DOI

http://dx.doi.org/10.1007/s11657-019-0564-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1111918752

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30719589


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Northern General Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412937.a", 
          "name": [
            "Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK", 
            "Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Herries Road, S57AU, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McCloskey", 
        "givenName": "E. V.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radius Health (United States)", 
          "id": "https://www.grid.ac/institutes/grid.488375.5", 
          "name": [
            "Radius Health, Inc., Waltham, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fitzpatrick", 
        "givenName": "L. A.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radius Health (United States)", 
          "id": "https://www.grid.ac/institutes/grid.488375.5", 
          "name": [
            "Radius Health, Inc., Waltham, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "M.-Y.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Radius Health (United States)", 
          "id": "https://www.grid.ac/institutes/grid.488375.5", 
          "name": [
            "Radius Health, Inc., Waltham, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Williams", 
        "givenName": "G.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Sheffield", 
          "id": "https://www.grid.ac/institutes/grid.11835.3e", 
          "name": [
            "Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kanis", 
        "givenName": "J. A.", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1210/en.2015-1726", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000474083"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-015-3173-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008573629", 
          "https://doi.org/10.1007/s00198-015-3173-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.2991", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014567735"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.3042", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015191279"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0786-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020522189", 
          "https://doi.org/10.1007/s00198-008-0786-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-008-0786-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020522189", 
          "https://doi.org/10.1007/s00198-008-0786-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2016.11136", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021041547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200105103441904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021777316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.2301", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024252590"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jama.2016.11032", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026150326"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.1606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045972813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.1606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045972813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0543-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048434929", 
          "https://doi.org/10.1007/s00198-007-0543-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00198-007-0543-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048434929", 
          "https://doi.org/10.1007/s00198-007-0543-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2014-3718", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064295512"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1214/aoms/1177731601", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064402368"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jbmr.3163", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085171575"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/med/9780198713340.003.0004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1089111977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)32640-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099685023"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "We evaluated the efficacy of abaloparatide in women who were at increased risk for fracture, based on CHMP recommended risk thresholds, at the\u00a0Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) study\u00a0baseline. Among patients at high risk\u00a0based on FRAX probabilities, 18\u00a0months of abaloparatide significantly decreased risk for all fracture endpoints compared with placebo.\nPURPOSE: Abaloparatide, a novel anabolic agent for the treatment of postmenopausal osteoporosis, significantly reduced the risk of vertebral and nonvertebral fractures in the ACTIVE study compared with placebo. In this post hoc analysis, we evaluated abaloparatide's efficacy in a subset of women in the study at an increased risk of fracture at baseline, based on the Committee for Medicinal Products for Human Use (CHMP) recommended risk thresholds for inclusion in clinical trials.\nMETHODS: Women with a baseline 10-year risk of major osteoporotic fracture \u2265\u200910% or hip fracture \u2265\u20095%, assessed using the FRAX\u00ae tool (including femoral neck bone mineral density), were included in the analysis. The proportion with one or more events of new morphometric vertebral fractures was calculated. Event rates for nonvertebral, major osteoporotic, and all clinical fractures were estimated using Kaplan-Meier analysis.\nRESULTS: Following 18\u00a0months of treatment, abaloparatide significantly reduced incident vertebral fractures compared with placebo (relative risk reduction\u2009=\u200991%; 0.5% versus 5.6%; p\u2009<\u20090.001). Abaloparatide treatment was also associated with significantly fewer nonvertebral, major osteoporotic, and clinical fractures compared with placebo: 2.7% versus 5.8%, p\u2009=\u20090.036; 1.3% versus 6.0%, p\u2009<\u20090.001; and 3.5% versus 8.2%, p\u2009=\u20090.006, respectively. The effect of abaloparatide on major osteoporotic fractures (78% reduction) was significantly greater than that seen with teriparatide (23% reduction, p\u2009=\u20090.007).\nCONCLUSION: In a subset of postmenopausal women at increased risk of fracture as judged by CHMP guidance, abaloparatide significantly decreased the risk of all fracture endpoints compared with placebo.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11657-019-0564-7", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1039144", 
        "issn": [
          "1862-3522", 
          "1862-3514"
        ], 
        "name": "Archives of Osteoporosis", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "14"
      }
    ], 
    "name": "Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability", 
    "pagination": "15", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "f5042776c97ec0d039ddb8a09c60958ee2224bf037e57675a3fce32225d36c8c"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30719589"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101318988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11657-019-0564-7"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1111918752"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11657-019-0564-7", 
      "https://app.dimensions.ai/details/publication/pub.1111918752"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T11:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000354_0000000354/records_11728_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11657-019-0564-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11657-019-0564-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11657-019-0564-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11657-019-0564-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11657-019-0564-7'


 

This table displays all metadata directly associated to this object as RDF triples.

150 TRIPLES      21 PREDICATES      45 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11657-019-0564-7 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 schema:author Ndd3b9fa190634dd9a027b0a365a7c091
4 schema:citation sg:pub.10.1007/s00198-007-0543-5
5 sg:pub.10.1007/s00198-008-0786-9
6 sg:pub.10.1007/s00198-015-3173-3
7 https://doi.org/10.1001/jama.2016.11032
8 https://doi.org/10.1001/jama.2016.11136
9 https://doi.org/10.1002/jbmr.1606
10 https://doi.org/10.1002/jbmr.2301
11 https://doi.org/10.1002/jbmr.2991
12 https://doi.org/10.1002/jbmr.3042
13 https://doi.org/10.1002/jbmr.3163
14 https://doi.org/10.1016/s0140-6736(17)32640-5
15 https://doi.org/10.1056/nejm200105103441904
16 https://doi.org/10.1093/med/9780198713340.003.0004
17 https://doi.org/10.1210/en.2015-1726
18 https://doi.org/10.1210/jc.2014-3718
19 https://doi.org/10.1214/aoms/1177731601
20 schema:datePublished 2019-12
21 schema:datePublishedReg 2019-12-01
22 schema:description We evaluated the efficacy of abaloparatide in women who were at increased risk for fracture, based on CHMP recommended risk thresholds, at the Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) study baseline. Among patients at high risk based on FRAX probabilities, 18 months of abaloparatide significantly decreased risk for all fracture endpoints compared with placebo. PURPOSE: Abaloparatide, a novel anabolic agent for the treatment of postmenopausal osteoporosis, significantly reduced the risk of vertebral and nonvertebral fractures in the ACTIVE study compared with placebo. In this post hoc analysis, we evaluated abaloparatide's efficacy in a subset of women in the study at an increased risk of fracture at baseline, based on the Committee for Medicinal Products for Human Use (CHMP) recommended risk thresholds for inclusion in clinical trials. METHODS: Women with a baseline 10-year risk of major osteoporotic fracture ≥ 10% or hip fracture ≥ 5%, assessed using the FRAX® tool (including femoral neck bone mineral density), were included in the analysis. The proportion with one or more events of new morphometric vertebral fractures was calculated. Event rates for nonvertebral, major osteoporotic, and all clinical fractures were estimated using Kaplan-Meier analysis. RESULTS: Following 18 months of treatment, abaloparatide significantly reduced incident vertebral fractures compared with placebo (relative risk reduction = 91%; 0.5% versus 5.6%; p < 0.001). Abaloparatide treatment was also associated with significantly fewer nonvertebral, major osteoporotic, and clinical fractures compared with placebo: 2.7% versus 5.8%, p = 0.036; 1.3% versus 6.0%, p < 0.001; and 3.5% versus 8.2%, p = 0.006, respectively. The effect of abaloparatide on major osteoporotic fractures (78% reduction) was significantly greater than that seen with teriparatide (23% reduction, p = 0.007). CONCLUSION: In a subset of postmenopausal women at increased risk of fracture as judged by CHMP guidance, abaloparatide significantly decreased the risk of all fracture endpoints compared with placebo.
23 schema:genre research_article
24 schema:inLanguage en
25 schema:isAccessibleForFree false
26 schema:isPartOf N15f3222706904c17b29c47ecbf8acf1a
27 N733cd91d04f14cecaf5d3f07028a9809
28 sg:journal.1039144
29 schema:name Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability
30 schema:pagination 15
31 schema:productId N324b3af6d3414a41933c9f347bf99dc7
32 N350dd7bf37c84a77824712a35489c602
33 N69829d7fff4c4f6c9efa7ce55255383f
34 N7291058d23ff46feb2a65492bb9a3f96
35 Nae84adc527f94b649b2a53c9edefbc6d
36 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111918752
37 https://doi.org/10.1007/s11657-019-0564-7
38 schema:sdDatePublished 2019-04-11T11:21
39 schema:sdLicense https://scigraph.springernature.com/explorer/license/
40 schema:sdPublisher N9a2c562723c448788d27d03ef67f7058
41 schema:url https://link.springer.com/10.1007%2Fs11657-019-0564-7
42 sgo:license sg:explorer/license/
43 sgo:sdDataset articles
44 rdf:type schema:ScholarlyArticle
45 N0e8fe2ad0f22437c85dd691ad6f3fee4 schema:affiliation https://www.grid.ac/institutes/grid.488375.5
46 schema:familyName Williams
47 schema:givenName G.
48 rdf:type schema:Person
49 N11a9ccc840df403e82bdafd55cc4d793 schema:affiliation https://www.grid.ac/institutes/grid.488375.5
50 schema:familyName Hu
51 schema:givenName M.-Y.
52 rdf:type schema:Person
53 N15f3222706904c17b29c47ecbf8acf1a schema:volumeNumber 14
54 rdf:type schema:PublicationVolume
55 N1cce8eedabfb45188eecd4f4bfe469e5 rdf:first N70e9cb3c3887455f8c432753426be0cc
56 rdf:rest rdf:nil
57 N324b3af6d3414a41933c9f347bf99dc7 schema:name readcube_id
58 schema:value f5042776c97ec0d039ddb8a09c60958ee2224bf037e57675a3fce32225d36c8c
59 rdf:type schema:PropertyValue
60 N350dd7bf37c84a77824712a35489c602 schema:name doi
61 schema:value 10.1007/s11657-019-0564-7
62 rdf:type schema:PropertyValue
63 N3ce7cf7711bc41589b556afb65ff654a schema:affiliation https://www.grid.ac/institutes/grid.412937.a
64 schema:familyName McCloskey
65 schema:givenName E. V.
66 rdf:type schema:Person
67 N59fc6248eacb41deb4715d402df52532 rdf:first N0e8fe2ad0f22437c85dd691ad6f3fee4
68 rdf:rest N1cce8eedabfb45188eecd4f4bfe469e5
69 N69829d7fff4c4f6c9efa7ce55255383f schema:name pubmed_id
70 schema:value 30719589
71 rdf:type schema:PropertyValue
72 N6a73e3c9d93c4e058b286ef821d9d454 rdf:first N11a9ccc840df403e82bdafd55cc4d793
73 rdf:rest N59fc6248eacb41deb4715d402df52532
74 N6e313019095b409bbb4362e4ba0b52bd schema:affiliation https://www.grid.ac/institutes/grid.488375.5
75 schema:familyName Fitzpatrick
76 schema:givenName L. A.
77 rdf:type schema:Person
78 N70e9cb3c3887455f8c432753426be0cc schema:affiliation https://www.grid.ac/institutes/grid.11835.3e
79 schema:familyName Kanis
80 schema:givenName J. A.
81 rdf:type schema:Person
82 N7291058d23ff46feb2a65492bb9a3f96 schema:name nlm_unique_id
83 schema:value 101318988
84 rdf:type schema:PropertyValue
85 N72debd6c8cf14d68aa689ea1fd1ada52 rdf:first N6e313019095b409bbb4362e4ba0b52bd
86 rdf:rest N6a73e3c9d93c4e058b286ef821d9d454
87 N733cd91d04f14cecaf5d3f07028a9809 schema:issueNumber 1
88 rdf:type schema:PublicationIssue
89 N9a2c562723c448788d27d03ef67f7058 schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 Nae84adc527f94b649b2a53c9edefbc6d schema:name dimensions_id
92 schema:value pub.1111918752
93 rdf:type schema:PropertyValue
94 Ndd3b9fa190634dd9a027b0a365a7c091 rdf:first N3ce7cf7711bc41589b556afb65ff654a
95 rdf:rest N72debd6c8cf14d68aa689ea1fd1ada52
96 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
97 schema:name Medical and Health Sciences
98 rdf:type schema:DefinedTerm
99 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
100 schema:name Clinical Sciences
101 rdf:type schema:DefinedTerm
102 sg:journal.1039144 schema:issn 1862-3514
103 1862-3522
104 schema:name Archives of Osteoporosis
105 rdf:type schema:Periodical
106 sg:pub.10.1007/s00198-007-0543-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048434929
107 https://doi.org/10.1007/s00198-007-0543-5
108 rdf:type schema:CreativeWork
109 sg:pub.10.1007/s00198-008-0786-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020522189
110 https://doi.org/10.1007/s00198-008-0786-9
111 rdf:type schema:CreativeWork
112 sg:pub.10.1007/s00198-015-3173-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008573629
113 https://doi.org/10.1007/s00198-015-3173-3
114 rdf:type schema:CreativeWork
115 https://doi.org/10.1001/jama.2016.11032 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026150326
116 rdf:type schema:CreativeWork
117 https://doi.org/10.1001/jama.2016.11136 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021041547
118 rdf:type schema:CreativeWork
119 https://doi.org/10.1002/jbmr.1606 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045972813
120 rdf:type schema:CreativeWork
121 https://doi.org/10.1002/jbmr.2301 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024252590
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1002/jbmr.2991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014567735
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1002/jbmr.3042 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015191279
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1002/jbmr.3163 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085171575
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/s0140-6736(17)32640-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099685023
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1056/nejm200105103441904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021777316
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1093/med/9780198713340.003.0004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1089111977
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1210/en.2015-1726 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000474083
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1210/jc.2014-3718 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064295512
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1214/aoms/1177731601 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064402368
140 rdf:type schema:CreativeWork
141 https://www.grid.ac/institutes/grid.11835.3e schema:alternateName University of Sheffield
142 schema:name Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
143 rdf:type schema:Organization
144 https://www.grid.ac/institutes/grid.412937.a schema:alternateName Northern General Hospital
145 schema:name Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
146 Metabolic Bone Centre, Sorby Wing, Northern General Hospital, Herries Road, S57AU, Sheffield, UK
147 rdf:type schema:Organization
148 https://www.grid.ac/institutes/grid.488375.5 schema:alternateName Radius Health (United States)
149 schema:name Radius Health, Inc., Waltham, MA, USA
150 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...